NBIX
Neurocrine Biosciences, Inc.

3,228
Mkt Cap
$15.19B
Volume
964,285.00
52W High
$157.67
52W Low
$84.23
PE Ratio
35.83
NBIX Fundamentals
Price
$150.02
Prev Close
$152.37
Open
$152.97
50D MA
$142.23
Beta
0.68
Avg. Volume
933,591.91
EPS (Annual)
$3.29
P/B
4.98
Rev/Employee
$1.31M
Loading...
Loading...
News
all
press releases
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with...
PR Newswire·10h ago
News Placeholder
More News
News Placeholder
Pier 88 Investment Partners LLC Sells 3,680 Shares of Neurocrine Biosciences, Inc. $NBIX
Pier 88 Investment Partners LLC cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 43.0% in the 2nd quarter, according to its most recent Form 13F filing with the...
MarketBeat·19h ago
News Placeholder
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 19,454.9% during the 2nd quarter, according to the company in its most...
MarketBeat·2d ago
News Placeholder
William Rastetter Sells 18,000 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director William Rastetter sold 18,000 shares of the business's stock in a transaction that occurred on Wednesday, November 5th. The...
MarketBeat·3d ago
News Placeholder
Neurocrine Biosciences (NASDAQ:NBIX) Director William Rastetter Sells 18,000 Shares
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director William Rastetter sold 18,000 shares of the firm's stock in a transaction on Wednesday, November 5th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
C WorldWide Group Holding A S Acquires 20,000 Shares of Neurocrine Biosciences, Inc. $NBIX
C WorldWide Group Holding A S raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 17.4% in the 2nd quarter, according to the company in its most recent Form...
MarketBeat·4d ago
News Placeholder
Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks·5d ago
News Placeholder
Neurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week High - Should You Buy?
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 1-Year High - Still a Buy...
MarketBeat·5d ago
News Placeholder
What Makes Neurocrine (NBIX) a New Strong Buy Stock
Neurocrine (NBIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·7d ago
News Placeholder
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Zacks·7d ago

Latest NBIX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.